Literature DB >> 30102356

Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats.

Jay S Mishra1, Amar S More2, Kathirvel Gopalakrishnan1, Sathish Kumar1,3.   

Abstract

Sex hormones contribute to sex differences in blood pressure. Inappropriate activation of the renin-angiotensin system is involved in vascular dysfunction and hypertension. This study evaluated the role of androgens (testosterone) in angiotensin II (Ang II)-induced increase in blood pressure, vascular reactivity, and cardiac hypertrophy. Eight-week-old male Wistar rats underwent sham operation, castration, or castration with testosterone replacement. After 12 weeks of chronic changes in androgen status, Ang II (120 ng/kg per minute) or saline was infused for 28 days via subcutaneous miniosmotic pump, and changes in blood pressure was measured. Vascular reactivity and Ang II receptor levels were examined in mesenteric arteries. Heart weight, cardiac ANP mRNA levels, and fibrosis were also assessed. Ang II infusion increased arterial pressure in intact males. The Ang II-induced increase in hypertensive response was prevented in castrated males. Testosterone replacement in castrated males restored Ang II-induced hypertensive responses. Castration reduced vascular AT1R/AT2R ratio, an effect that was reversed by testosterone replacement. Ang II-induced hypertension was associated with increased contractile response of mesenteric arteries to Ang II and phenylephrine in intact and testosterone-replaced castrated males; these increases were prevented in castrated males. Ang II infusion induced increased left ventricle-to-body weight ratio and ANP mRNA expression, indicators of left ventricular hypertrophy, and fibrosis in intact and testosterone-replaced castrated males, and castration prevented the increase in these parameters caused by Ang II. This study demonstrates that testosterone plays a permissive role in development and maintenance of Ang II-induced vascular dysfunction, hypertension, and cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30102356      PMCID: PMC6335213          DOI: 10.1093/biolre/ioy179

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  66 in total

1.  Temporal alterations in vascular angiotensin receptors and vasomotor responses in offspring of protein-restricted rat dams.

Authors:  Kunju Sathishkumar; Meena Balakrishnan; Vijayakumar Chinnathambi; Haijun Gao; Chandra Yallampalli
Journal:  Am J Obstet Gynecol       Date:  2012-04-06       Impact factor: 8.661

2.  Angiotensin and cell growth: a link to cardiovascular hypertrophy?

Authors:  P Schelling; H Fischer; D Ganten
Journal:  J Hypertens       Date:  1991-01       Impact factor: 4.844

3.  Elevated testosterone levels during rat pregnancy cause hypersensitivity to angiotensin II and attenuation of endothelium-dependent vasodilation in uterine arteries.

Authors:  Vijayakumar Chinnathambi; Chellakkan S Blesson; Kathleen L Vincent; George R Saade; Gary D Hankins; Chandra Yallampalli; Kunju Sathishkumar
Journal:  Hypertension       Date:  2014-05-19       Impact factor: 10.190

4.  Atrial natriuretic factor gene expression in ventricles of rats with spontaneous biventricular hypertrophy.

Authors:  R T Lee; K D Bloch; J M Pfeffer; M A Pfeffer; E J Neer; C E Seidman
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 5.  Sex and gender differences in myocardial hypertrophy and heart failure.

Authors:  Vera Regitz-Zagrosek; Sabine Oertelt-Prigione; Ute Seeland; Roland Hetzer
Journal:  Circ J       Date:  2010-06-15       Impact factor: 2.993

6.  Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Authors:  Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan M Edelman; Kristian Wachtell
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

Review 7.  Androgens and cardiovascular disease.

Authors:  Peter Y Liu; Alison K Death; David J Handelsman
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

8.  Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Sumiko Yoshida; Takashi Sato; Shusuke Yagi; Takashi Iwase; Yuka Sumitomo; Takayuki Ise; Kazue Ishikawa; Hiroyuki Azuma; Masashi Akaike; Shigeaki Kato; Toshio Matsumoto
Journal:  Endocrinology       Date:  2009-02-05       Impact factor: 4.736

9.  Testosterone downregulates angiotensin II type-2 receptor via androgen receptor-mediated ERK1/2 MAP kinase pathway in rat aorta.

Authors:  Jay S Mishra; Gary D Hankins; Sathish Kumar
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-10-19       Impact factor: 1.636

10.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more
  11 in total

1.  TLR4 regulates vascular smooth muscle cell proliferation in hypertension via modulation of the NLRP3 inflammasome.

Authors:  Hui-Meng Qi; Qin Cao; Qiang Liu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Gender Differences in Cardiac Hypertrophy.

Authors:  Jian Wu; Fangjie Dai; Chang Li; Yunzeng Zou
Journal:  J Cardiovasc Transl Res       Date:  2019-08-15       Impact factor: 4.132

3.  Relative risk of plaque erosion among different age and sex groups in patients with acute coronary syndrome.

Authors:  Hyung Oh Kim; Chong Jin Kim; Weon Kim; Jin-Man Cho; Tsunenari Soeda; Masamichi Takano; Bryan P Yan; Filippo Crea; Giampaolo Niccoli; Rocco Vergallo; Yoshiyasu Minami; Takumi Higuma; Shigeki Kimura; Niklas Frederik Boeder; Holger Nef; Tom Adriaenssens; Osamu Kurihara; Vikas Thondapu; Michele Russo; Erika Yamamoto; Tomoyo Sugiyama; Hang Lee; Tsunekazu Kakuta; Taishi Yonetsu; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

Review 4.  Neurodegenerative Disease: Roles for Sex, Hormones, and Oxidative Stress.

Authors:  Nathalie Sumien; J Thomas Cunningham; Delaney L Davis; Rachel Engelland; Oluwadarasimi Fadeyibi; George E Farmer; Steve Mabry; Paapa Mensah-Kane; Oanh T P Trinh; Philip H Vann; E Nicole Wilson; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

Review 5.  Sex Differences in the Prevalence, Outcomes and Management of Hypertension.

Authors:  Paul J Connelly; Gemma Currie; Christian Delles
Journal:  Curr Hypertens Rep       Date:  2022-03-07       Impact factor: 4.592

Review 6.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

7.  Repurposing existing drugs for COVID-19: an endocrinology perspective.

Authors:  Flavio A Cadegiani
Journal:  BMC Endocr Disord       Date:  2020-09-29       Impact factor: 2.763

8.  Brain Testosterone-CYP1B1 (Cytochrome P450 1B1) Generated Metabolite 6β-Hydroxytestosterone Promotes Neurogenic Hypertension and Inflammation.

Authors:  Purnima Singh; Shubha Ranjan Dutta; Chi Young Song; SaeRam Oh; Frank J Gonzalez; Kafait U Malik
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

9.  Possible protective role of 17β-estradiol against COVID-19.

Authors:  Nabab Khan
Journal:  J Allergy Infect Dis       Date:  2020-08-19

10.  Association of free androgen index and sex hormone-binding globulin and left ventricular hypertrophy in postmenopausal hypertensive women.

Authors:  Chen Jianshu; Wang Qiongying; Pei Ying; Li Ningyin; Han Junchen; Yu Jing
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.